Abstract
It has been estimated that approx 60–70% of cancer patients harbor overt or subclinical metastases at diagnosis, and it is the eradication of such systemic disease that largely determines survival. Preclinical tumor model systems employed to evaluate potential new treatment strategies should aim to represent the process and patterns of metastasis of their clinical counterparts as closely as possible. Severe combined immune-deficient (SCID) andnu/nu mice have been extensively used as hosts for the growth of human tumor cell lines and in some cases fresh tumor material. However, in most instances the resulting neoplasms fail to metastasize, and the aberrant immune systems of such animals has limited their use mainly to passive therapies of localized disease. Recently, the development of specially selected tumor variants and the use of appropriate orthotopic sites for implantation has provided several models in which dissemination can be demonstrated. Where the gene coding for a potential target antigen has been cloned, and where its overexpression or mutation is associated with malignancy (e.g., c-erbB-2, H-ras), transgenic mice may yield tumors that will develop in these immunocompetent hosts. In some cases such tumors exhibit metastasis. A third approach is to transfect human genes of interest into appropriate rodent tumors expressing the desired metastatic phenotype. These various approaches are compared with particular reference to mammary carcinoma biology.
Similar content being viewed by others
References
Miller, A. B. and Bullbrook, R. D. (1986)Int. J. Ca. 37, 173.
Bailar, J. C. and Smith, E. M. (1986)N. Engl. J. Med. 314, 1226.
Early breast cancer trialists' collaborative group (1992)Lancet 339, 71.
Manzotti, C., Audisio, R. A., and Pratesi, G. (1993)Clin. Exp. Met. 11, 5.
Harris, A. L., Nicholson, S., Sainsbury, J., Farndon, J. and Wright, C. (1989)J. Steroid Biochem. 34, 123.
Pierce, J., Arnstein, P., DiMarco, E., Artrip, J., Kraus, M., Lonardo, F., et al. (1991)Oncogene 6, 1189.
Kurachi, H., Okamoto, S., and Oka, T. (1985)Proc. Natl. Acad. Sci. USA 82, 5940.
Hudziak, R., Lewis, G., Winget, M., Fendly, B., Shepard, H., and Ullrich, A. (1989)Mol. Cell Biol. 9, 1165.
Masui, H., Kawamoto, T., Sato, J., Wolf, B., Sato, G., and Mendelsohn, J. (1984)Cancer Res. 44, 1002.
Modjtahedi, H., Eccles, S., Box, G., Styles, J., and Dean, C. (1993)Br. J. Cancer 67, 254.
Price, J. and Zhang, R. D. (1990)Cancer Met. Rev. 8, 285.
Giovanella, B., Vardeman, D., Williams, L., Taylor, D., Ipolyi, P., Greeff P., et al. (1991)Int. J. Cancer 47, 66.
Brunner, N., Osborne, C. K., and Spang-Thomsen, M. (1987)Breast Cancer Res. Treat. 10, 229.
Mueller, B. and Reisfeld, R. A. (1991)Cancer Met. Rev. 10, 193.
Kerbel, R. S., Cornil, I., and Theodorescu, D. (1991)Cancer Met. Rev. 10, 201.
Thompson, E. W., Brunner, N., Torri, J., Johnson, M. D., Boulay, V., Wright, A., et al. (1993)Clin. Exp. Met. 11, 15.
Kurebayashi, J., McLeskey, S., Johnson, M., Lippman, M., Dickson, R., and Kern, F. (1993)Cancer Res. 53, 2178.
Long, B., McKibben, B., Lynch, M., and van den Berg, H. (1992)Br. J. Cancer 65, 865.
Muller, W. J. (1991)Cancer Met. Rev. 10, 217.
Muller, W. J., Sinn, E., Pattengale, P., Wallace, R., and Leder, P. (1988)Cell 54, 105.
Lemoine, N., Staddon, S., Dickson, C., Barnes, D. M., and Gullick, W. J. (1990)Oncogene 5, 237.
Guy, C., Webster, M., Schaller, M., Parsons, T., Cardiff, R., and Muller, W. (1992)Proc. Natl. Acad. Sci. USA 89, 10578.
Narisawa, S., Smans, K., Avis, J., Hoylaerts, M., and Millan, J. (1993)Proc. Natl. Acad. Sci. USA 90, 5081.
Nishiyama, A., Dahlin, K., Prince, J., Johnstone, S., and Stallcup, W. (1991)J. Cell. Biol. 114, 359.
Léger, O., Dunn, P. L., Coles, B., and Dean, C. J. (1991)Int. J. Cancer 47, 569.
Eccles, S. A., Box, G., Court, W., Collins, M. K., and Dean, C. J. (1993)Cell Biophys. 21–23, in press.
Russell, S. J., Eccles, S. A., Flemming, C. L., Johnson, C. A., and Collins, M. K. L. (1991)Int. J. Cancer 47, 244.
Wijsman, J., Cornelisse, C. J., Keijzer, R., van de Velde, C., and Dierendonck, J. H. (1991)Br. J. Cancer 64, 463.
Davies, B. R., Davies, M., Gibbs, F., Barraclough, R., and Rudland, P. S. (1993)Oncogene 8, 999.
Jarrett, A. and Eccles, S. (1992)Br. J. Cancer 65, 976.
Carnochan, P., Trivedi, M., Young, H., Eccles, S., Potter, G., Haynes, B., et al., (1993)J. Nucl. Biol. Med. in press.
Eccles, S. A. (1992)Cellular Immune Mechanisms in Tumor Dormancy (Stewart, T. and Wheelock, F., eds.), CRC Press, Boca Raton, FL, p. 27.
Ormerod, M. G., Titley, J. C., Smith, T., Tombs, A. J., and Eccles, S. A. (1993)Br. J. Cancer 67, 107.
Smith, T., Eccles, S. A., Ormerod, M. G., Tombs, A. J., Titley, J. C., and Leach, M. O. (1991)Br. J. Cancer 64, 821.
Tiwari, R., Borgen, P., Wong, G., Cordon-Cardo, C., and Osborne, M. (1992)Anticancer Res. 12, 419.
Kallioniemi, O., Holli, K., Visakorpi, T., Koivula, T., Helin, H., and Isola, J. (1991)Int. J. Cancer 49, 650.
Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., and de Bortoli, M. (1990)Oncogene 5, 1001.
Lalani, L-N., Berdichevsky, F., Boshell, M., Shearer, M., Wilson, D., Stauss, H., et al. (1991)J. Biol. Chem. 266, 15420.
Bakir, M., Eccles, S., Babich, J., Aftab, N., Styles, J., Dean, C., et al. (1992)J. Nucl. Med. 33, 2154.
Allan, S., Dean, C., Fernando, I., Eccles, S., Styles, J., McCready, R., et al. (1993)Br. J. Cancer 67, 706.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eccles, S.A., Box, G., Court, W. et al. Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell Biophysics 24, 279–291 (1994). https://doi.org/10.1007/BF02789239
Issue Date:
DOI: https://doi.org/10.1007/BF02789239